{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:54:59Z","timestamp":1792018499494,"version":"4.4.0"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RTI2018-098672-B-I00"],"award-info":[{"award-number":["RTI2018-098672-B-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["IT1587-22"],"award-info":[{"award-number":["IT1587-22"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["GIC21\/34"],"award-info":[{"award-number":["GIC21\/34"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003086","name":"Eusko Jaurlaritza","doi-asserted-by":"publisher","award":["PRE_2020_2_01164"],"award-info":[{"award-number":["PRE_2020_2_01164"]}],"id":[{"id":"10.13039\/501100003086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003451","name":"Euskal Herriko Unibertsitatea","doi-asserted-by":"publisher","award":["PIF21\/61"],"award-info":[{"award-number":["PIF21\/61"]}],"id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003451","name":"Universidad del Pa\u00eds Vasco","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003451","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40259-024-00674-1","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:45:56Z","timestamp":1724456756000},"page":"657-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems"],"prefix":"10.1007","volume":"38","author":[{"given":"Marina","family":"Beraza-Millor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julen","family":"Rodr\u00edguez-Castej\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"del Pozo-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Rodr\u00edguez-Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-0775","authenticated-orcid":false,"given":"Mar\u00eda \u00c1ngeles","family":"Solin\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,23]]},"reference":[{"key":"674_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","volume":"66","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med. 2015;66:471\u201386.","journal-title":"Annu Rev Med"},{"key":"674_CR2","doi-asserted-by":"crossref","unstructured":"Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4:27","DOI":"10.1038\/s41572-018-0025-4"},{"key":"674_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1479-7364-5-3-156","volume":"5","author":"M Filocamo","year":"2011","unstructured":"Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics. 2011;5:156\u201369.","journal-title":"Hum Genomics"},{"key":"674_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.4155\/fmc-2017-0065","volume":"9","author":"C Arenz","year":"2017","unstructured":"Arenz C. Recent advances and novel treatments for sphingolipidoses. Future Med Chem. 2017;9:1685\u201398.","journal-title":"Future Med Chem"},{"key":"674_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21072515","volume":"21","author":"S Fecarotta","year":"2020","unstructured":"Fecarotta S, Tarallo A, Damiano C, Minopoli N, Parenti G. Pathogenesis of mucopolysaccharidoses, an update. Int J Mol Sci. 2020;21:1\u201314.","journal-title":"Int J Mol Sci"},{"key":"674_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186812","volume":"21","author":"SA Khan","year":"2020","unstructured":"Khan SA, Tomatsu SC. Mucolipidoses overview: past, present, and future. Int J Mol Sci. 2020;21:1\u201320.","journal-title":"Int J Mol Sci"},{"key":"674_CR7","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1530\/JOE-18-0120","volume":"238","author":"SS Ellingwood","year":"2018","unstructured":"Ellingwood SS, Cheng A. Biochemical and clinical aspects of glycogen storage diseases. J Endocrinol. 2018;238:R131\u201341.","journal-title":"J Endocrinol"},{"key":"674_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.202012836","volume":"13","author":"G Parenti","year":"2021","unstructured":"Parenti G, Medina DL, Ballabio A. The rapidly evolving view of lysosomal storage diseases. EMBO Mol Med. 2021;13:1\u201321.","journal-title":"EMBO Mol Med"},{"key":"674_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beem.2014.08.004","volume":"29","author":"SDK Kingma","year":"2015","unstructured":"Kingma SDK, Bodamer OA, Wijburg FA. Epidemiology and diagnosis of lysosomal storage disorders; challenges of screening. Best Pract Res Clin Endocrinol Metab. 2015;29:145\u201357.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"674_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ymgme.2021.05.004","volume":"133","author":"Y Koto","year":"2021","unstructured":"Koto Y, Sakai N, Lee Y, Kakee N, Matsuda J, Tsuboi K, et al. Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: a nationwide survey in Japan. Mol Genet Metab. 2021;133:277\u201388.","journal-title":"Mol Genet Metab"},{"key":"674_CR11","unstructured":"The portal for rare diseases and orphan drugs. Orpha.net https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease.php?lng=EN. Accessed 16 Apr 2024."},{"key":"674_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000448968","volume":"134","author":"D Oder","year":"2016","unstructured":"Oder D, Nordbeck P, Wanner C. Long term treatment with enzyme replacement therapy in patients with Fabry disease. Nephron. 2016;134:30\u20136.","journal-title":"Nephron"},{"key":"674_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms22147699","volume":"22","author":"T Dinur","year":"2021","unstructured":"Dinur T, Grittner U, Revel-Vilk S, Becker-Cohen M, Istaiti M, Cozma C, et al. Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-gb1) values in patients with type 1 Gaucher disease: statistical models for comparing three enzymatic formulations. Int J Mol Sci. 2021;22:1\u201311.","journal-title":"Int J Mol Sci"},{"key":"674_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom11121775","volume":"11","author":"C Fern\u00e1ndez-Pereira","year":"2021","unstructured":"Fern\u00e1ndez-Pereira C, Mill\u00e1n-Tejado BS, Gallardo-G\u00f3mez M, P\u00e9rez-M\u00e1rquez T, Alves-Villar M, Melc\u00f3n-Crespo C, et al. Therapeutic approaches in lysosomal storage diseases. Biomolecules. 2021;11:1\u201319.","journal-title":"Biomolecules"},{"key":"674_CR15","doi-asserted-by":"publisher","first-page":"15172","DOI":"10.1073\/pnas.0607053103","volume":"103","author":"WS Sly","year":"2006","unstructured":"Sly WS, Vogler C, Grubb JH, Levy B, Galvin N, Tan Y, et al. Enzyme therapy in mannose receptor-null mucopolysaccharidosis VII mice defines roles for the mannose 6-phosphate and mannose receptors. Proc Natl Acad Sci USA. 2006;103:15172\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"674_CR16","doi-asserted-by":"publisher","first-page":"13532","DOI":"10.1074\/jbc.RA119.009811","volume":"295","author":"JC Chen","year":"2020","unstructured":"Chen JC, Luu AR, Wise N, de Angelis R, Agrawal V, Mangini L, et al. Intracerebroventricular enzyme replacement therapy with \u03b2-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice. J Biol Chem. 2020;295:13532\u201355.","journal-title":"J Biol Chem"},{"key":"674_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JMFG, Poorthuis BJHM, Groener JEM, Donker-Koopman W, Hendriks E, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS ONE. 2012;7:1\u20137.","journal-title":"PLoS ONE"},{"key":"674_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","volume":"118","author":"M Solomon","year":"2017","unstructured":"Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives. Adv Drug Deliv Rev. 2017;118:109\u201334.","journal-title":"Adv Drug Deliv Rev"},{"key":"674_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409816666297","volume":"4","author":"S Ortolano","year":"2016","unstructured":"Ortolano S. Small molecules: substrate inhibitors, chaperones, stop-codon read through, and beyond. J Inborn Errors Metab Screen. 2016;4:1\u201311.","journal-title":"J Inborn Errors Metab Screen."},{"key":"674_CR20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","volume":"13","author":"O Jung","year":"2017","unstructured":"Jung O, Patnaik S, Marugan J, Sidransky E, Westbroek W. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its potential implications for Parkinson disease. Expert Rev Proteomics. 2017;13:471\u20139.","journal-title":"Expert Rev Proteomics"},{"key":"674_CR21","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54:288\u201396.","journal-title":"J Med Genet"},{"key":"674_CR22","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23:1138\u201348.","journal-title":"Mol Ther"},{"key":"674_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00731489","volume":"13","author":"NS Radin","year":"1996","unstructured":"Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J. 1996;13:153\u20137.","journal-title":"Glycoconj J"},{"key":"674_CR24","doi-asserted-by":"crossref","unstructured":"Asmamaw M, Zawdie B. Mechanism and applications of CRISPR\/Cas-9-mediated genome editing. Biologics. 2021;15:353\u201361.","DOI":"10.2147\/BTT.S326422"},{"key":"674_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/eci.14039","volume":"53","author":"MAM Redhwan","year":"2023","unstructured":"Redhwan MAM, Hariprasad MG, Samaddar S, Hard SAAA, Yadav V, Mukherjee A, et al. Small interference (RNAi) technique: exploring its clinical applications, benefits and limitations. Eur J Clin Invest. 2023;53:1\u201314.","journal-title":"Eur J Clin Invest"},{"key":"674_CR26","first-page":"393","volume":"29","author":"BM Chris","year":"2010","unstructured":"Chris BM, Elizabeth HG, Huang MT-H, Debra JT. Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol. 2010;29:393\u20135.","journal-title":"Methods Mol Biol"},{"key":"674_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpls.2020.01237","volume":"11","author":"P Svoboda","year":"2020","unstructured":"Svoboda P. Key mechanistic principles and considerations concerning RNA interference. Front Plant Sci. 2020;11:1\u201313.","journal-title":"Front Plant Sci"},{"key":"674_CR28","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.2174\/0929867325666180403141554","volume":"26","author":"S Naghizadeh","year":"2018","unstructured":"Naghizadeh S, Mansoori B, Mohammadi A, Sakhinia E, Baradaran B. Gene silencing strategies in cancer therapy: an update for drug resistance. Curr Med Chem. 2018;26:6282\u2013303.","journal-title":"Curr Med Chem"},{"key":"674_CR29","unstructured":"Onpattro | Highlights of prescribing information. Dailymed.nlm.nih.gov https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e87ec36f-b4b4-49d4-aea4-d4ffb09b0970. Accessed 16 Apr 2024."},{"key":"674_CR30","unstructured":"Givlaari | European Medicines Agency. Ema.europa.ue\/en. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/givlaari. Accessed 16 Apr 2024."},{"key":"674_CR31","unstructured":"Oxlumo | European Medicines Agency. Ema.europa.ue\/en. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/oxlumo. Accessed 16 Apr 2024."},{"key":"674_CR32","unstructured":"Leqvio | European Medicines Agency. Ema.europa.ue\/en. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqvio. Accessed 16 Apr 2024."},{"key":"674_CR33","unstructured":"Amvuttra | European Medicines Agency. Ema.europa.ue\/en. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/famvuttra. Accessed 16 Apr 2024."},{"key":"674_CR34","unstructured":"Rivfloza | Highlights of prescribing information. Dailymed.nlm.nih.gov https:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=ace9d4bc-4d20-4beb-9e9d-888690424833. Accessed 16 Apr 2024."},{"key":"674_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100416","volume":"296","author":"ST Crooke","year":"2021","unstructured":"Crooke ST, Liang XH, Baker BF, Crooke RM. Antisense technology: a review. J Biol Chem. 2021;296: 100416.","journal-title":"J Biol Chem"},{"key":"674_CR36","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/bab.2028","volume":"68","author":"SM Gheibi-Hayat","year":"2021","unstructured":"Gheibi-Hayat SM, Jamialahmadi K. Antisense oligonucleotide (AS-ODN) technology: principle, mechanism and challenges. Biotechnol Appl Biochem. 2021;68:1086\u201394.","journal-title":"Biotechnol Appl Biochem"},{"key":"674_CR37","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.3390\/ijms22073295","volume":"22","author":"H Xiong","year":"2021","unstructured":"Xiong H, Veedu RN, Diermeier SD. Recent advances in oligonucleotide therapeutics in oncology. Int J Mol Sci. 2021;22:3295.","journal-title":"Int J Mol Sci"},{"key":"674_CR38","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.bbmt.2018.03.021","volume":"24","author":"LAM Rein","year":"2018","unstructured":"Rein LAM, Yang H, Chao NJ. Applications of gene editing technologies to cellular therapies. Biol Blood Marrow Transplant. 2018;24:1537\u201345.","journal-title":"Biol Blood Marrow Transplant"},{"key":"674_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578:229\u201336.","journal-title":"Nature"},{"key":"674_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jgm.3108","volume":"21","author":"F Wang","year":"2019","unstructured":"Wang F, Qin Z, Lu H, He S, Luo J, Jin C, et al. Clinical translation of gene medicine. J Gene Med. 2019;21:1\u20138.","journal-title":"J Gene Med"},{"key":"674_CR41","first-page":"127","volume":"123","author":"A del Pozo-Rodr\u00edguez","year":"2019","unstructured":"del Pozo-Rodr\u00edguez A, Rodr\u00edguez-Gasc\u00f3n A, Rodr\u00edguez-Castej\u00f3n J, Vicente-Pascual M, G\u00f3mez-Aguado I, Battaglia LS, et al. Gene therapy. Adv Biochem Eng Biotechnol. 2019;123:127\u201341.","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"674_CR42","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.","journal-title":"BMJ"},{"key":"674_CR43","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1476-5381.2010.00872.x","volume":"160","author":"C Kilkenny","year":"2010","unstructured":"Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160:1577\u20139.","journal-title":"Br J Pharmacol"},{"key":"674_CR44","first-page":"1","volume":"2200423","author":"IG Kim","year":"2023","unstructured":"Kim IG, Jung WH, You G, Lee H, Shin YJ, Lim SW, et al. Efficient delivery of globotriaosylceramide synthase siRNA using polyhistidine-incorporated lipid nanoparticles. Macromol Biosci. 2023;2200423:1\u201310.","journal-title":"Macromol Biosci"},{"key":"674_CR45","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.3390\/pharmaceutics15071936","volume":"15","author":"M Beraza-Millor","year":"2023","unstructured":"Beraza-Millor M, Rodr\u00edguez-Castej\u00f3n J, Miranda J, del Pozo-Rodr\u00edguez A, Rodr\u00edguez-Gasc\u00f3n A, Solin\u00eds M\u00c1. Novel golden lipid nanoparticles with small interference ribonucleic acid for substrate reduction therapy in Fabry disease. Pharmaceutics. 2023;15:1936.","journal-title":"Pharmaceutics"},{"key":"674_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.trsl.2023.02.005","volume":"258","author":"S Cui","year":"2023","unstructured":"Cui S, Shin YJ, Fang X, Lee H, Eum SH, Ko EJ, et al. CRISPR\/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model. Transl Res. 2023;258:35\u201346.","journal-title":"Transl Res"},{"key":"674_CR47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bcmd.2006.07.002","volume":"37","author":"A Diaz-Font","year":"2006","unstructured":"Diaz-Font A, Chab\u00e1s A, Grinberg D, Vilageliu L. RNAi-mediated inhibition of the glucosylceramide synthase (GCS) gene: a preliminary study towards a therapeutic strategy for Gaucher disease and other glycosphingolipid storage diseases. Blood Cells Mol Dis. 2006;37:197\u2013203.","journal-title":"Blood Cells Mol Dis"},{"key":"674_CR48","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1093\/hmg\/ddn290","volume":"17","author":"G Douillard-Guilloux","year":"2008","unstructured":"Douillard-Guilloux G, Raben N, Takikita S, Batista L, Caillaud C, Richard E. Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Hum Mol Genet. 2008;17:3876\u201386.","journal-title":"Hum Mol Genet"},{"key":"674_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.57","volume":"3","author":"NP Clayton","year":"2014","unstructured":"Clayton NP, Nelson CA, Weeden T, Taylor KM, Moreland RJ, Scheule RK, et al. Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of pompe disease. Mol Ther Nucleic Acids. 2014;3: e206.","journal-title":"Mol Ther Nucleic Acids."},{"key":"674_CR50","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/ejhg.2009.143","volume":"18","author":"X Kaidonis","year":"2010","unstructured":"Kaidonis X, Liaw WC, Roberts AD, Ly M, Anson D, Byers S. Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses. Eur J Hum Genet. 2010;18:194\u20139.","journal-title":"Eur J Hum Genet"},{"key":"674_CR51","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/ejhg.2009.144","volume":"18","author":"D Dziedzic","year":"2010","unstructured":"Dziedzic D, Wgrzyn G, Jak\u00f3bkiewicz-Banecka J. Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur J Hum Genet. 2010;18:200\u20135.","journal-title":"Eur J Hum Genet"},{"key":"674_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.18388\/abp.2012_2154","volume":"59","author":"D Dziedzic","year":"2012","unstructured":"Dziedzic D, Narajczyk M, Gabig-Cimi\u0144ska M, Jak\u00f3bkiewicz-Banecka J. Simultaneous siRNA-mediated silencing of pairs of genes coding for enzymes involved in glycosaminoglycan synthesis. Acta Biochim Pol. 2012;59:293\u20138.","journal-title":"Acta Biochim Pol"},{"key":"674_CR53","doi-asserted-by":"publisher","first-page":"697","DOI":"10.18388\/abp.2012_2113","volume":"59","author":"I Chmielarz","year":"2012","unstructured":"Chmielarz I, Gabig-Ciminska M, Malinowska M, Banecka-Majkutewicz Z, Wegrzyn A, Jakobkiewicz-Banecka J. Comparison of siRNA-mediated silencing of glycosaminoglycan synthesis genes and enzyme replacement therapy for mucopolysaccharidosis in cell culture studies. Acta Biochim Pol. 2012;59:697\u2013702.","journal-title":"Acta Biochim Pol"},{"key":"674_CR54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/srep13654","volume":"5","author":"I Canals","year":"2015","unstructured":"Canals I, Benet\u00f3 N, Cozar M, Vilageliu L, Grinberg D. EXTL2 and EXTL3 inhibition with siRNAs as a promising substrate reduction therapy for Sanfilippo C syndrome. Sci Rep. 2015;5:3\u20137.","journal-title":"Sci Rep"},{"key":"674_CR55","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2020","unstructured":"Felis A, Whitlow M, Kraus A, Warnock DG, Wallace E. Current and investigational therapeutics for Fabry disease. Kidney Int Rep. 2020;5:407\u201313.","journal-title":"Kidney Int Rep."},{"key":"674_CR56","volume":"31","author":"C Wanner","year":"2022","unstructured":"Wanner C, Kimonis V, Politei J, Warnock DG, \u00dc\u00e7eyler N, Frey A, et al. Understanding and modifying Fabry disease: rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study. Mol Genet Metab Rep. 2022;31: 100862.","journal-title":"Mol Genet Metab Rep."},{"key":"674_CR57","doi-asserted-by":"crossref","unstructured":"Deegan PB, Goker-Alpan O, Geberhiwot T, Hopkin RJ, Lukina E, Tylki-Szymanska A, et al. Venglustat, an orally administered glucosylceramide synthase inhibitor: assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study. Mol Genet Metab. 2023;138:106963.","DOI":"10.1016\/j.ymgme.2022.11.002"},{"key":"674_CR58","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Saladelafont E, Fern\u00e1ndez-Mart\u00edn J, Ortolano S. Fabry disease and central nervous system involvement: from big to small, from brain to synapse. Int J Mol Sci. 2023;24:5246.","DOI":"10.3390\/ijms24065246"},{"key":"674_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2019.129437","volume":"1864","author":"JJ Miller","year":"2020","unstructured":"Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease. Biochim Biophys Acta Gen Subj. 2020;1864: 129437.","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"674_CR60","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","volume":"132","author":"NJ Weinreb","year":"2021","unstructured":"Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment. Mol Genet Metab. 2021;132:100\u201311.","journal-title":"Mol Genet Metab"},{"key":"674_CR61","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bcmd.2016.10.007","volume":"68","author":"A Zimran","year":"2018","unstructured":"Zimran A, Elstein D, Gonzalez DE, Lukina EA, Qin Y, Dinh Q, et al. Treatment-na\u00efve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4 years in phase 3 trials. Blood Cells Mol Dis. 2018;68:153\u20139.","journal-title":"Blood Cells Mol Dis"},{"key":"674_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02289-7","volume":"17","author":"L Titievsky","year":"2022","unstructured":"Titievsky L, Schuster T, Wang R, Younus M, Palladino A, Quazi K, et al. Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS). Orphanet J Rare Dis. 2022;17:1\u201311.","journal-title":"Orphanet J Rare Dis"},{"key":"674_CR63","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1021\/acschemneuro.0c00558","volume":"11","author":"MW Wilson","year":"2020","unstructured":"Wilson MW, Shu L, Hinkovska-Galcheva V, Jin Y, Rajeswaran W, Abe A, et al. Optimization of eliglustat-based glucosylceramide synthase inhibitors as substrate reduction therapy for Gaucher disease type 3. ACS Chem Neurosci. 2020;11:3464\u201373.","journal-title":"ACS Chem Neurosci"},{"key":"674_CR64","doi-asserted-by":"crossref","unstructured":"Kong W, Lu C, Ding Y, Meng Y. Update of treatment for Gaucher disease. Eur J Pharmacol. 2022;926:175023.","DOI":"10.1016\/j.ejphar.2022.175023"},{"key":"674_CR65","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.pedneo.2013.03.009","volume":"54","author":"YH Chien","year":"2013","unstructured":"Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol. 2013;54:219\u201327.","journal-title":"Pediatr Neonatol"},{"key":"674_CR66","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1212\/WNL.0000000000002523","volume":"86","author":"BJ Ebbink","year":"2016","unstructured":"Ebbink BJ, Poelman E, Plug I, Lequin MH, van Doorn PA, Aarsen FK, et al. Cognitive decline in classic infantile Pompe disease: an underacknowledged challenge. Neurology. 2016;86:1260\u20131.","journal-title":"Neurology"},{"key":"674_CR67","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/dmcn.13740","volume":"60","author":"BJ Ebbink","year":"2018","unstructured":"Ebbink BJ, Poelman E, Aarsen FK, Plug I, R\u00e9gal L, Muentjes C, et al. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol. 2018;60:579\u201386.","journal-title":"Dev Med Child Neurol"},{"key":"674_CR68","first-page":"19","volume":"59","author":"R Giugliani","year":"2018","unstructured":"Giugliani R. Mucopolysacccharidoses: from investigation to treatment, a century of discoveries. Investig Clin. 2018;59:19\u201320.","journal-title":"Investig Clin"},{"key":"674_CR69","doi-asserted-by":"crossref","unstructured":"Filocamo M, Tomanin R, Bertola F, Morrone A. Biochemical and molecular analysis in mucopolysaccharidoses: what a paediatrician must know. Ital J Pediatr. 2018;44:129.","DOI":"10.1186\/s13052-018-0553-2"},{"key":"674_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2019.165539","volume":"1865","author":"V De Pasquale","year":"2019","unstructured":"De Pasquale V, Pavone LM. Heparan sulfate proteoglycans: the sweet side of development turns sour in mucopolysaccharidoses. Biochim Biophys Acta Mol Basis Dis. 2019;1865: 165539.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"674_CR71","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/ped.12636","volume":"57","author":"F Andrade","year":"2015","unstructured":"Andrade F, Ald\u00e1miz-Echevarr\u00eda L, Llarena M, Couce ML. Sanfilippo syndrome: overall review. Pediatr Int. 2015;57:331\u20138.","journal-title":"Pediatr Int"},{"key":"674_CR72","unstructured":"Mepsevii | European Medicines Agency. Ema.europa.ue\/en. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mepsevii. Accessed 16 Apr 2024."},{"key":"674_CR73","doi-asserted-by":"crossref","unstructured":"Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44:120.","DOI":"10.1186\/s13052-018-0562-1"},{"key":"674_CR74","doi-asserted-by":"crossref","unstructured":"Tucci F, Consiglieri G, Cossutta M, Bernardo ME, Maria C, Bernardo ME. Current and future perspective in hematopoietic stem progenitor cell-gene therapy for inborn errors of metabolism. Hemasphere. 2020;7:e953.","DOI":"10.1097\/HS9.0000000000000953"},{"key":"674_CR75","doi-asserted-by":"crossref","unstructured":"Hampe CS, Wesley J, Lund TC, Orchard PJ, Polgreen LE, Eisengart JB, et al. Mucopolysaccharidosis type I: current treatments, limitations, and prospects for improvement. Biomolecules. 2021;11:189.","DOI":"10.3390\/biom11020189"},{"key":"674_CR76","doi-asserted-by":"crossref","unstructured":"Benet\u00f3 N, Vilageliu L, Grinberg D. Sanfilippo syndrome: molecular basis, disease models and therapeutic approaches. Int J Mol Sci. 2020;21:7819.","DOI":"10.3390\/ijms21217819"},{"key":"674_CR77","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","volume":"79","author":"K Sawamoto","year":"2019","unstructured":"Sawamoto K, Stapleton M, Alm\u00e9ciga-D\u00edaz CJ, Espejo-Mojica AJ, Losada JC, Suarez DA, et al. Therapeutic options for mucopolysaccharidoses: current and emerging treatments. Drugs. 2019;79:1103\u201334.","journal-title":"Drugs"},{"key":"674_CR78","doi-asserted-by":"crossref","unstructured":"Annaval T, Wild R, Cr\u00e9tinon Y, Sadir R, Viv\u00e8s RR, Lortat-Jacob H. Heparan sulfate proteoglycans biosynthesis and post synthesis mechanisms combine few enzymes and few core proteins to generate extensive structural and functional diversity. Molecules. 2020;25:4215.","DOI":"10.3390\/molecules25184215"},{"key":"674_CR79","doi-asserted-by":"crossref","unstructured":"Xu W, Jiang X, Huang L, Sciences B, Sar HK. RNA interference technology. Comprehensive biotechnology. 2019;560\u201375.","DOI":"10.1016\/B978-0-444-64046-8.00282-2"},{"key":"674_CR80","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40259-022-00549-3","volume":"36","author":"M Friedrich","year":"2022","unstructured":"Friedrich M, Aigner A. Therapeutic siRNA: state of the art and future perspectives. BioDrugs. 2022;36:549\u201371.","journal-title":"BioDrugs"},{"key":"674_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174178","volume":"905","author":"W Alshaer","year":"2021","unstructured":"Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal MM, et al. siRNA: mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021;905: 174178.","journal-title":"Eur J Pharmacol"},{"key":"674_CR82","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bbrc.2006.02.049","volume":"342","author":"S Choung","year":"2006","unstructured":"Choung S, Kim YJ, Kim S, Park HO, Choi YC. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun. 2006;342:919\u201327.","journal-title":"Biochem Biophys Res Commun"},{"key":"674_CR83","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.addr.2009.04.004","volume":"61","author":"DD Rao","year":"2009","unstructured":"Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev. 2009;61:746\u201359.","journal-title":"Adv Drug Deliv Rev"},{"key":"674_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-017-0101-9","volume":"6","author":"S Aguiar","year":"2017","unstructured":"Aguiar S, van der Gaag B, Cortese FAB. RNAi mechanisms in Huntington\u2019s disease therapy: SiRNA versus shRNA. Transl Neurodegener. 2017;6:1\u201310.","journal-title":"Transl Neurodegener."},{"key":"674_CR85","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.colsurfb.2016.07.026","volume":"146","author":"J Torrecilla","year":"2016","unstructured":"Torrecilla J, del Pozo-Rodr\u00edguez A, Solin\u00eds M\u00c1, Apaolaza PS, Berzal-Herranz B, Romero-L\u00f3pez C, et al. Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES). Colloids Surfaces B Biointerfaces. 2016;146:808\u201317.","journal-title":"Colloids Surfaces B Biointerfaces."},{"key":"674_CR86","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1089\/nat.2018.0725","volume":"28","author":"MF Osborn","year":"2018","unstructured":"Osborn MF, Khvorova A. Improving siRNA delivery in vivo through lipid conjugation. Nucleic Acid Ther. 2018;28:128\u201336.","journal-title":"Nucleic Acid Ther"},{"key":"674_CR87","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40291-018-0338-8","volume":"22","author":"F Liu","year":"2018","unstructured":"Liu F, Wang C, Gao Y, Li X, Tian F, Zhang Y, et al. Current transport systems and clinical applications for small interfering RNA (siRNA) drugs. Mol Diagnosis Ther. 2018;22:551\u201369.","journal-title":"Mol Diagnosis Ther."},{"key":"674_CR88","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41587-023-02105-y","volume":"42","author":"V Jadhav","year":"2024","unstructured":"Jadhav V, Vaishnaw A, Fitzgerald K, Maier MA. RNA interference in the era of nucleic acid therapeutics. Nat Biotechnol. 2024;42:394\u2013405.","journal-title":"Nat Biotechnol"},{"key":"674_CR89","first-page":"316","volume":"334","author":"FK Askari","year":"2012","unstructured":"Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. Mol Med. 2012;334:316\u20138.","journal-title":"Mol Med"},{"key":"674_CR90","doi-asserted-by":"crossref","unstructured":"Oberemok V, Laikova KV, Repetskaya AI, Kenyo IM, Gorlov M V, Kasich IN, et al. A half-century history of applications of antisense oligonucleotides in medicine, agriculture and forestry: we should continue the journey. Molecules. 2018;23:1302.","DOI":"10.3390\/molecules23061302"},{"key":"674_CR91","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40520-019-01360-x","volume":"33","author":"G Biamonti","year":"2021","unstructured":"Biamonti G, Amato A, Belloni E, Di Matteo A, Infantino L, Pradella D, et al. Alternative splicing in Alzheimer\u2019s disease. Aging Clin Exp Res. 2021;33:747\u201358.","journal-title":"Aging Clin Exp Res"},{"key":"674_CR92","doi-asserted-by":"crossref","unstructured":"Amanat M, Nemeth CL, Fine AS, Leung DG, Fatemi A. Antisense oligonucleotide therapy for the nervous system: from bench to bedside with emphasis on pediatric neurology. Pharmaceutics. 2022;14:2389.","DOI":"10.3390\/pharmaceutics14112389"},{"key":"674_CR93","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jcb.26154","volume":"119","author":"JuX Da","year":"2018","unstructured":"Da JuX, Xu J, Sun ZS. CRISPR editing in biological and biomedical investigation. J Cell Biochem. 2018;119:52\u201361.","journal-title":"J Cell Biochem"},{"key":"674_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-018-1518-x","volume":"19","author":"T Guo","year":"2018","unstructured":"Guo T, Feng YL, Xiao JJ, Liu Q, Sun XN, Xiang JF, et al. Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR\/Cas9-mediated genome editing. Genome Biol. 2018;19:1\u201320.","journal-title":"Genome Biol"},{"key":"674_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2019.00001","volume":"10","author":"M Liu","year":"2019","unstructured":"Liu M, Rehman S, Tang X, Gu K, Fan Q, Chen D, et al. Methodologies for improving HDR efficiency. Front Genet. 2019;10:1\u20139.","journal-title":"Front Genet"},{"key":"674_CR96","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2020","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2020;25:249\u201354.","journal-title":"Nat Med"},{"key":"674_CR97","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","volume":"9","author":"JM Crudele","year":"2018","unstructured":"Crudele JM, Chamberlain JS. Cas9 immunity creates challenges for CRISPR gene editing therapies. Nat Commun. 2018;9:3497.","journal-title":"Nat Commun"},{"key":"674_CR98","unstructured":"Casvegy. | Highlights of prescribing information. Dailymed.nlm.nih.gov. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7c3e12ad-e2fe-4d3f-a630-ea7364d9e846 . Accessed 16 Apr 2024."},{"key":"674_CR99","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, Chen Y-S, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384:252\u201360.","journal-title":"N Engl J Med"},{"key":"674_CR100","doi-asserted-by":"crossref","unstructured":"Coutinho MF, Santos JI, Alves S. Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci. 2016;17:1065.","DOI":"10.3390\/ijms17071065"},{"key":"674_CR101","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nmeth854","volume":"3","author":"A Birmingham","year":"2006","unstructured":"Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, et al. 3\u2019 UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods. 2006;3:199\u2013204.","journal-title":"Nat Methods"},{"key":"674_CR102","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00294-019-01040-3","volume":"66","author":"A Barman","year":"2020","unstructured":"Barman A, Deb B, Chakraborty S. A glance at genome editing with CRISPR\u2013Cas9 technology. Curr Genet. 2020;66:447\u201362.","journal-title":"Curr Genet"},{"key":"674_CR103","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Aguado I, Rodr\u00edguez-Castej\u00f3n J, Beraza-Millor M, Rodr\u00edguez-Gasc\u00f3n A, del Pozo-Rodr\u00edguez A, Solin\u00eds M\u00c1. mRNA delivery technologies: toward clinical translation. Int Rev Cell Mol Biol. 2022;372:207\u201393.","DOI":"10.1016\/bs.ircmb.2022.04.010"},{"key":"674_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/btm2.10213","volume":"6","author":"M Schlich","year":"2021","unstructured":"Schlich M, Palomba R, Costabile G, Mizrahy S, Pannuzzo M, Peer D, et al. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng Transl Med. 2021;6:1\u201316.","journal-title":"Bioeng Transl Med."},{"key":"674_CR105","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1021\/mp3003336","volume":"9","author":"W De Haes","year":"2012","unstructured":"De Haes W, Van Mol G, Merlin C, De Smedt SC, Vanham G, Rejman J. Internalization of mRNA lipoplexes by dendritic cells. Mol Pharm. 2012;9:2942\u20139.","journal-title":"Mol Pharm"},{"key":"674_CR106","doi-asserted-by":"crossref","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:53.","DOI":"10.1038\/s41392-021-00487-6"},{"key":"674_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-98657-7","volume":"11","author":"V Kalidasan","year":"2021","unstructured":"Kalidasan V, Ng WH, Ishola OA, Ravichantar N, Tan JJ, Das KT. A guide in lentiviral vector production for hard-to-transfect cells, using cardiac-derived c-kit expressing cells as a model system. Sci Rep. 2021;11:1\u201311.","journal-title":"Sci Rep"},{"key":"674_CR108","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1038\/sj.gt.3301893","volume":"9","author":"JB Connoly","year":"2002","unstructured":"Connoly JB. Lentiviruses in gene therapy clinical reseach. Gene Ther. 2002;9:1730\u20134.","journal-title":"Gene Ther"},{"key":"674_CR109","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/mt.2012.23","volume":"21","author":"S Scaramuzza","year":"2013","unstructured":"Scaramuzza S, Biasco L, Ripamonti A, Castiello MC, Loperfido M, Draghici E, et al. Preclinical safety and efficacy of human CD34 + cells transduced with lentiviral vector for the treatment of wiskott-aldrich syndrome. Mol Ther. 2013;21:175\u201384.","journal-title":"Mol Ther"},{"key":"674_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7717\/peerj.13704","volume":"10","author":"CHT Yew","year":"2022","unstructured":"Yew CHT, Gurumoorthy N, Nordin F, Tye GJ, Zaman WSWK, Tan JJ, et al. Integrase deficient lentiviral vector: prospects for safe clinical applications. PeerJ. 2022;10:1\u201336.","journal-title":"PeerJ"},{"key":"674_CR111","first-page":"139","volume":"103","author":"N Slade","year":"2001","unstructured":"Slade N. Viral vectors in gene therapy. Period Biol. 2001;103:139\u201343.","journal-title":"Period Biol"},{"key":"674_CR112","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0003-4975(96)00946-0","volume":"62","author":"MG Kaplitt","year":"1996","unstructured":"Kaplitt MG, Xiao X, Samulski RJ, Li J, Ojamaa K, Klein IL, et al. Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann Thorac Surg. 1996;62:1669\u201376.","journal-title":"Ann Thorac Surg"},{"key":"674_CR113","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrg2988","volume":"12","author":"F Mingozzi","year":"2011","unstructured":"Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12:341\u201355.","journal-title":"Nat Rev Genet"},{"key":"674_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v11010028","volume":"11","author":"CL Xu","year":"2019","unstructured":"Xu CL, Ruan MZC, Mahajan VB, Tsang SH. Viral delivery systems for CRISPR. Viruses. 2019;11:1\u201312.","journal-title":"Viruses"},{"key":"674_CR115","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nbt.3469","volume":"34","author":"Y Yang","year":"2016","unstructured":"Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34:334\u20138.","journal-title":"Nat Biotechnol"},{"key":"674_CR116","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.ijbiomac.2021.05.192","volume":"183","author":"D Sharma","year":"2021","unstructured":"Sharma D, Arora S, Singh J, Layek B. A review of the tortuous path of non-viral gene delivery and recent progress. Int J Biol Macromol. 2021;183:2055\u201373.","journal-title":"Int J Biol Macromol"},{"key":"674_CR117","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nrg1066","volume":"4","author":"CE Thomas","year":"2003","unstructured":"Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346\u201358.","journal-title":"Nat Rev Genet"},{"key":"674_CR118","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/v15091801","volume":"15","author":"Y Wang","year":"2023","unstructured":"Wang Y, Shao W. Innate immune response to viral vectors in gene therapy. Viruses. 2023;15:1801.","journal-title":"Viruses"},{"key":"674_CR119","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","volume":"171","author":"L Li","year":"2018","unstructured":"Li L, Hu S, Chen X. Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities. Biomaterials. 2018;171:207\u201318.","journal-title":"Biomaterials"},{"key":"674_CR120","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"H Yin","year":"2014","unstructured":"Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15:541\u201355.","journal-title":"Nat Rev Genet"},{"key":"674_CR121","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/gt.2017.5","volume":"24","author":"SRJ Guan","year":"2017","unstructured":"Guan SRJ. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther. 2017;24:133\u201343.","journal-title":"Gene Ther"},{"key":"674_CR122","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","volume":"86","author":"RW Malone","year":"1989","unstructured":"Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA. 1989;86:6077\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"674_CR123","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.3390\/molecules23102564","volume":"23","author":"T Wang","year":"2018","unstructured":"Wang T, Larcher LM, Ma L, Veedu RN. Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides. Molecules. 2018;23:2564.","journal-title":"Molecules"},{"key":"674_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113930","volume":"177","author":"ML Ibba","year":"2021","unstructured":"Ibba ML, Ciccone G, Esposito CL, Catuogno S, Giangrande PH. Advances in mRNA non-viral delivery approaches. Adv Drug Deliv Rev. 2021;177: 113930.","journal-title":"Adv Drug Deliv Rev"},{"key":"674_CR125","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Cullis PR, Van Der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28:146\u201357.","journal-title":"Nucleic Acid Ther"},{"key":"674_CR126","doi-asserted-by":"publisher","first-page":"14141","DOI":"10.1039\/C9NR02297J","volume":"11","author":"M Ramezanpour","year":"2019","unstructured":"Ramezanpour M, Schmidt ML, Bodnariuc I, Kulkarni JA, Leung SSW, Cullis PR, et al. Ionizable amino lipid interactions with POPC: implications for lipid nanoparticle function. Nanoscale. 2019;11:14141\u20136.","journal-title":"Nanoscale"},{"key":"674_CR127","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/wrna.1288","volume":"6","author":"B Vallazza","year":"2015","unstructured":"Vallazza B, Petri S, Poleganov MA, Eberle F, Kuhn AN, Sahin U. Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdiscipl Rev RNA. 2015;6:471\u201399.","journal-title":"Wiley Interdiscipl Rev RNA."},{"key":"674_CR128","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","volume":"18","author":"M Zhang","year":"2020","unstructured":"Zhang M, Sun J, Li M, Jin X. Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice. Mol Ther Methods Clin Dev. 2020;18:702\u201312.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"674_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1557\/s43577-021-00169-2","volume":"46","author":"JL Andresen","year":"2021","unstructured":"Andresen JL, Fenton OS. Nucleic acid delivery and nanoparticle design for COVID vaccines. MRS Bull. 2021;46:1\u20138.","journal-title":"MRS Bull"},{"key":"674_CR130","doi-asserted-by":"publisher","first-page":"9656","DOI":"10.1021\/acsami.0c21507","volume":"13","author":"M Gisbert-Garzaran","year":"2021","unstructured":"Gisbert-Garzaran M, Lozano D, Matsumoto K, Komatsu A, Manzano M, Tamanoi F, et al. Designing mesoporous silica nanoparticles to overcome biological barriers by incorporating targeting and endosomal escape. ACS Appl Mater Interfaces. 2021;13:9656\u201366.","journal-title":"ACS Appl Mater Interfaces"},{"key":"674_CR131","first-page":"8111","volume":"33","author":"Y Wen","year":"2012","unstructured":"Wen Y, Guo Z, Du Z, Fang R, Wu H, Zeng X, et al. Serum tolerance and endosomal escape capacity of histidine-modified pDNA-loaded complexes based on polyamidoamine dendrimer derivatives. JBMT. 2012;33:8111\u201321.","journal-title":"JBMT."},{"key":"674_CR132","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/wnan.1339","volume":"7","author":"SL Qi Yang","year":"2015","unstructured":"Qi Yang SL. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscipl Rev Nanomed Nanobiotechnol. 2015;7:655\u201377.","journal-title":"Wiley Interdiscipl Rev Nanomed Nanobiotechnol."},{"key":"674_CR133","doi-asserted-by":"crossref","unstructured":"Shi D, Beasock D, Fessler A, Szebeni J, Y. Ljubimova JY, Afonin KA, et al. To PEGylate or not to PEGylate: immunological properties of nanomedicine\u2019s most popular component, poly(ethylene) glycol and its alternatives. Adv Drug Deliv Rev. 2022;180:114079.","DOI":"10.1016\/j.addr.2021.114079"},{"key":"674_CR134","doi-asserted-by":"publisher","first-page":"6686","DOI":"10.1016\/j.actbio.2013.01.038","volume":"9","author":"S Hirsj\u00e4rvi","year":"2013","unstructured":"Hirsj\u00e4rvi S, Dufort S, Bastiat G, Saulnier P, Passirani C, Coll JL, et al. Surface modification of lipid nanocapsules with polysaccharides: from physicochemical characteristics to in vivo aspects. Acta Biomater. 2013;9:6686\u201393.","journal-title":"Acta Biomater"},{"key":"674_CR135","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ijpharm.2011.12.052","volume":"425","author":"D Delgado","year":"2012","unstructured":"Delgado D, Gasc\u00f3n AR, Del Pozo-Rodr\u00edguez A, Echevarr\u00eda E, Ruiz De Garibay AP, Rodr\u00edguez JM, et al. Dextran-protamine-solid lipid nanoparticles as a non-viral vector for gene therapy: in vitro characterization and in vivo transfection after intravenous administration to mice. Int J Pharm. 2012;425:35\u201343.","journal-title":"Int J Pharm"},{"key":"674_CR136","doi-asserted-by":"crossref","unstructured":"Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther. 2008;16:1624\u201329.","DOI":"10.1038\/mt.2008.120"},{"key":"674_CR137","first-page":"252","volume":"6","author":"A Misra","year":"2003","unstructured":"Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 2003;6:252\u201373.","journal-title":"J Pharm Pharm Sci"},{"key":"674_CR138","doi-asserted-by":"crossref","unstructured":"Patel S, Athirasala A, Menezes PP, Ashwanikumar N, Zou T, Sahay G, Bertassoni LE. Messenger RNA delivery for tissue engineering and regenerative medicine applications. Tissue Eng Part A. 2019;25:91\u2013112.","DOI":"10.1089\/ten.tea.2017.0444"},{"key":"674_CR139","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ejpb.2014.05.004","volume":"87","author":"L Gastaldi","year":"2014","unstructured":"Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm. 2014;87:433\u201344.","journal-title":"Eur J Pharm Biopharm"},{"key":"674_CR140","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","volume":"22","author":"DS Hersh","year":"2016","unstructured":"Hersh DS, Wadajkar AS, Roberts N, Perez JG, Connolly NP, Frenkel V, Winkles JA, Woodworth GFKA. Evolving drug delivery strategies to overcome the blood brain barrier. Curr Pharm Des. 2016;22:1177\u201393.","journal-title":"Curr Pharm Des"},{"key":"674_CR141","first-page":"795","volume":"9","author":"R Alyautdin","year":"2014","unstructured":"Alyautdin R, Khalin I, Nafeeza MI, Haron MH, Kuznetsov D. Nanoscale drug delivery systems and the blood\u2013brain barrier. Int J Nanomed. 2014;9:795\u2013811.","journal-title":"Int J Nanomed"},{"key":"674_CR142","doi-asserted-by":"publisher","first-page":"17270","DOI":"10.1073\/pnas.0406214101","volume":"101","author":"DR Thakker","year":"2004","unstructured":"Thakker DR, Natt F, H\u00fcsken D, Maier R, M\u00fcller M, Van Der Putten H, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA. 2004;101:17270\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"674_CR143","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtn.2017.08.013","volume":"9","author":"C Helmschrodt","year":"2017","unstructured":"Helmschrodt C, H\u00f6bel S, Sch\u00f6niger S, Bauer A, Bonicelli J, Gringmuth M, et al. Polyethylenimine nanoparticle-mediated siRNA delivery to reduce \u03b1-synuclein expression in a model of Parkinson\u2019s disease. Mol Ther Nucleic Acids. 2017;9:57\u201368.","journal-title":"Mol Ther Nucleic Acids."},{"key":"674_CR144","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Castej\u00f3n J, Beraza-Millor M, Solin\u00eds M\u00c1, Rodr\u00edguez-Gasc\u00f3n A, del Pozo-Rodr\u00edguez A. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review. Drug Deliv Transl Res. 2024.","DOI":"10.1007\/s13346-024-01583-0"},{"key":"674_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100300","volume":"3","author":"S Maestro","year":"2021","unstructured":"Maestro S, Weber ND, Zabaleta N, Aldabe R, Gonzalez-Aseguinolaza G. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep. 2021;3: 100300.","journal-title":"JHEP Rep"},{"key":"674_CR146","doi-asserted-by":"publisher","first-page":"16259","DOI":"10.1021\/acsomega.1c01755","volume":"6","author":"H Cui","year":"2021","unstructured":"Cui H, Zhu X, Li S, Wang P, Fang J. Liver-targeted delivery of oligonucleotides with N-acetylgalactosamine conjugation. ACS Omega. 2021;6:16259\u201365.","journal-title":"ACS Omega"},{"key":"674_CR147","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","volume":"28","author":"AJ Debacker","year":"2020","unstructured":"Debacker AJ, Voutila J, Catley M, Blakey D, Habib N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol Ther. 2020;28:1759\u201371.","journal-title":"Mol Ther"},{"key":"674_CR148","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1021\/acs.molpharmaceut.0c01238","volume":"18","author":"MCP Mendon\u00e7a","year":"2021","unstructured":"Mendon\u00e7a MCP, Kont A, Aburto MR, Cryan JF, O\u2019Driscoll CM. Advances in the design of (nano)formulations for delivery of antisense oligonucleotides and small interfering RNA: focus on the central nervous system. Mol Pharm. 2021;18:1491\u2013506.","journal-title":"Mol Pharm"},{"key":"674_CR149","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119368","volume":"275","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Mahabady MK, Zabolian A, Abbaspour A, Fallahzadeh P, Noori M, et al. Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: current status with an emphasis on delivery systems. Life Sci. 2021;275: 119368.","journal-title":"Life Sci"},{"key":"674_CR150","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1039\/D0BM00809E","volume":"8","author":"S Masoudi Asil","year":"2020","unstructured":"Masoudi Asil S, Ahlawat J, Guillama Barroso G, Narayan M. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. Biomater Sci. 2020;8:4109\u201328.","journal-title":"Biomater Sci"},{"key":"674_CR151","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Pra\u00e7a C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34\u201347.","journal-title":"J Control Release"},{"key":"674_CR152","doi-asserted-by":"crossref","unstructured":"Zhao H, Bao XJ, Wang RZ, Li GL, Gao J, Ma SH, et al. Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes. Hum Gene Ther. 2011;22:207\u201315.","DOI":"10.1089\/hum.2010.111"},{"key":"674_CR153","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S1525-0016(02)00018-7","volume":"7","author":"Y Zhang","year":"2003","unstructured":"Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the promate brain following intravenous administration. Mol Ther. 2003;7:11\u20138.","journal-title":"Mol Ther"},{"key":"674_CR154","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acschemneuro.0c00076","volume":"11","author":"S Arora","year":"2020","unstructured":"Arora S, Sharma D, Singh J. GLUT-1: an effective target to deliver brain-derived neurotrophic factor gene across the blood brain barrier. ACS Chem Neurosci. 2020;11:1620\u201333.","journal-title":"ACS Chem Neurosci"},{"key":"674_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2013.01.016","volume":"167","author":"G Sharma","year":"2013","unstructured":"Sharma G, Modgil A, Layek B, Arora K, Sun C, Law B, et al. Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: biodistribution and transfection. J Control Release. 2013;167:1\u201310.","journal-title":"J Control Release"},{"key":"674_CR156","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jconrel.2018.07.043","volume":"286","author":"RB Dos Santos","year":"2018","unstructured":"Dos Santos RB, Oue H, Banerjee A, Kanekiyo T, Singh J. Dual functionalized liposome-mediated gene delivery across triple co-culture blood brain barrier model and specific in vivo neuronal transfection. J Control Release. 2018;286:264\u201378.","journal-title":"J Control Release"},{"key":"674_CR157","doi-asserted-by":"crossref","unstructured":"Dos Santos Rodrigues B, Kanekiyo T, Singh J. ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles. Pharm Res. 2019;36:161.","DOI":"10.1007\/s11095-019-2691-7"},{"key":"674_CR158","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1021\/acs.molpharmaceut.0c00218","volume":"17","author":"RB Dos Santos","year":"2020","unstructured":"Dos Santos RB, Kanekiyo T, Singh J. Nerve growth factor gene delivery across the blood brain barrier to reduce beta amyloid accumulation in AD mice. Mol Pharm. 2020;17:2054\u201363.","journal-title":"Mol Pharm"},{"key":"674_CR159","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.2147\/IJN.S215941","volume":"14","author":"RB Dos Santos","year":"2019","unstructured":"Dos Santos RB, Lakkadwala S, Kanekiyo T, Singh J. Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties. Int J Nanomed. 2019;14:6497\u2013517.","journal-title":"Int J Nanomed"},{"key":"674_CR160","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1124\/jpet.119.264127","volume":"374","author":"RB Dos Santos","year":"2020","unstructured":"Dos Santos RB, Lakkadwala S, Kanekiyo T, Singh J. Dual-modified liposome for targeted and enhanced gene delivery into mice brain. J Pharmacol Exp Ther. 2020;374:354\u201365.","journal-title":"J Pharmacol Exp Ther"},{"key":"674_CR161","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3390\/pharmaceutics14030672","volume":"14","author":"H Choi","year":"2022","unstructured":"Choi H, Choi K, Kim DH, Oh BK, Yim H, Jo S, et al. Strategies for targeted delivery of exosomes to the brain: advantages and challenges. Pharmaceutics. 2022;14:672.","journal-title":"Pharmaceutics"},{"key":"674_CR162","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijpharm.2016.06.127","volume":"510","author":"L Wei","year":"2016","unstructured":"Wei L, Guo XY, Yang T, Yu MZ, Chen DW, Wang JC. Brain tumor-targeted therapy by systemic delivery of siRNA with transferrin receptor-mediated core-shell nanoparticles. Int J Pharm. 2016;510:394\u2013405.","journal-title":"Int J Pharm"},{"key":"674_CR163","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/10717544.2013.838713","volume":"21","author":"D Mittal","year":"2014","unstructured":"Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014;21:75\u201386.","journal-title":"Drug Deliv"},{"key":"674_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-01819-9","volume":"7","author":"M Rodriguez","year":"2017","unstructured":"Rodriguez M, Lapierre J, Ojha CR, Kaushik A, Batrakova E, Kashanchi F, et al. Intranasal drug delivery of small interfering RNA targeting Beclin1 encapsulated with polyethylenimine (PEI) in mouse brain to achieve HIV attenuation. Sci Rep. 2017;7:1\u201310.","journal-title":"Sci Rep"},{"key":"674_CR165","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jgm.300","volume":"4","author":"N Tomita","year":"2002","unstructured":"Tomita N, Morishita R, Yamamoto K, Higaki J, Dzau VJ, Ogihara T, et al. Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. J Gene Med. 2002;4:527\u201335.","journal-title":"J Gene Med"},{"key":"674_CR166","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jconrel.2013.12.029","volume":"176","author":"PS Kowalski","year":"2014","unstructured":"Kowalski PS, Zwiers PJ, Morselt HWM, Kuldo JM, Leus NGJ, Ruiters MHJ, et al. Anti-VCAM-1 SAINT-O-Somes enable endothelial-specific delivery of siRNA and downregulation of inflammatory genes in activated endothelium in vivo. J Control Release. 2014;176:64\u201375.","journal-title":"J Control Release"},{"key":"674_CR167","doi-asserted-by":"publisher","first-page":"15856","DOI":"10.18632\/aging.103794","volume":"12","author":"S Taverna","year":"2020","unstructured":"Taverna S, Cammarata G, Colomba P, Sciarrino S, Zizzo C, Francofonte D, et al. Pompe disease: pathogenesis, molecular genetics and diagnosis. Aging. 2020;12:15856\u201374.","journal-title":"Aging"},{"key":"674_CR168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2020.00001","volume":"11","author":"Y Li","year":"2020","unstructured":"Li Y, Chen M, Zhao Y, Li M, Qin Y, Cheng S, et al. Advance in drug delivery for ageing skeletal muscle. Front Pharmacol. 2020;11:1\u20139.","journal-title":"Front Pharmacol"},{"key":"674_CR169","doi-asserted-by":"crossref","unstructured":"Vorrius B, Qiao Z, Ge J, Chen Q. Smart strategies to overcome drug delivery challenges in the musculoskeletal system. Pharmaceuticals. 2023;16:967.","DOI":"10.3390\/ph16070967"},{"key":"674_CR170","doi-asserted-by":"crossref","unstructured":"Meena NK, Raben N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules. 2020;10:1339.","DOI":"10.3390\/biom10091339"},{"key":"674_CR171","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4155\/tde-2017-0057","volume":"8","author":"D Van Haute","year":"2016","unstructured":"Van Haute D, Berlin JO. Challenges in realizing selectivity for nanoparticle biodistribution and clearance: lessons from gold nanoparticles. Ther Deliv. 2016;8:763\u201374.","journal-title":"Ther Deliv"},{"key":"674_CR172","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.2174\/1381612820666140929095755","volume":"21","author":"DC Ebner","year":"2015","unstructured":"Ebner DC, Bialek P, El-Kattan AF, Ambler CM, Tu M. Strategies for skeletal muscle targeting in drug discovery. Curr Pharm Des. 2015;21:1327\u201336.","journal-title":"Curr Pharm Des"},{"key":"674_CR173","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/(SICI)1097-4598(199904)22:4<460::AID-MUS6>3.0.CO;2-L","volume":"22","author":"TI Samoylova","year":"1999","unstructured":"Samoylova TI, Smith BF. Elucidation of muscle-binding peptides by phage display screening. Muscle Nerve. 1999;22:460\u20136.","journal-title":"Muscle Nerve"},{"key":"674_CR174","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.peptides.2010.06.036","volume":"31","author":"Y Seow","year":"2010","unstructured":"Seow Y, Yin H, Wood MJA. Identification of a novel muscle targeting peptide in mdx mice. Peptides. 2010;31:1873\u20137.","journal-title":"Peptides"},{"key":"674_CR175","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18:265\u201391.","journal-title":"Nat Protoc"},{"key":"674_CR176","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1039\/D0NA00863J","volume":"3","author":"N Singh","year":"2021","unstructured":"Singh N, Marets C, Boudon J, Millot N, Saviot L, Maurizi L. In vivo protein corona on nanoparticles: does the control of all material parameters orient the biological behavior? Nanoscale Adv. 2021;3:1209\u201329.","journal-title":"Nanoscale Adv."},{"key":"674_CR177","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jconrel.2019.10.028","volume":"316","author":"PPG Guimaraes","year":"2019","unstructured":"Guimaraes PPG, Zhang R, Spektor R, Tan M, Chung A, Billingsley MM, et al. Ionizable lipid nanoparticles encapsulating barcoded mRNA for accelerated in vivo delivery screening. J Control Release. 2019;316:404\u201317.","journal-title":"J Control Release"},{"key":"674_CR178","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3390\/pharmaceutics14102129","volume":"14","author":"K Godbout","year":"2022","unstructured":"Godbout K, Tremblay JP. Delivery of RNAs to specific organs by lipid nanoparticles for gene therapy. Pharmaceutics. 2022;14:2129.","journal-title":"Pharmaceutics"},{"key":"674_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-17029-3","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11:1\u201312.","journal-title":"Nat Commun"},{"key":"674_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2018.00361","volume":"9","author":"M Matloka","year":"2018","unstructured":"Matloka M, Klein AF, Rau F, Furling D. Cells of matter-in vitro models for myotonic dystrophy. Front Neurol. 2018;9:1\u20139.","journal-title":"Front Neurol"},{"key":"674_CR181","first-page":"487","volume":"10","author":"L Arandel","year":"2017","unstructured":"Arandel L, Espizonoza MP, Bazinet AM, Diniz DDD, Naouar FR, et al. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds. Dis Model Mech. 2017;10:487\u201397.","journal-title":"Dis Model Mech"},{"key":"674_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9081780","volume":"9","author":"J Massenet","year":"2020","unstructured":"Massenet J, Gitiaux C, Magnan M, Cuvellier S, Hubas A, Nusbaum P, et al. Derivation and characterization of immortalized human muscle satellite cell clones from muscular dystrophy patients and healthy individuals. Cells. 2020;9:1\u201319.","journal-title":"Cells"},{"key":"674_CR183","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ymgme.2007.06.003","volume":"92","author":"JS Shen","year":"2007","unstructured":"Shen JS, Meng XL, Schiffmann R, Brady RO, Kaneski CR. Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab. 2007;92:137\u201344.","journal-title":"Mol Genet Metab"},{"key":"674_CR184","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663\u201376.","journal-title":"Cell"},{"key":"674_CR185","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1152\/physiol.00036.2016","volume":"32","author":"K Duval","year":"2017","unstructured":"Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg JCZ. Modeling physiological events in 2D vs. 3D cell culture. Physiology. 2017;32:266\u201377.","journal-title":"Physiology"},{"key":"674_CR186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-74191-w","volume":"10","author":"GDM Jeffries","year":"2020","unstructured":"Jeffries GDM, Xu S, Lobovkina T, Kirejev V, Tusseau F, Gyllensten C, et al. 3D micro-organisation printing of mammalian cells to generate biological tissues. Sci Rep. 2020;10:1\u201310.","journal-title":"Sci Rep"},{"key":"674_CR187","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacbts.2019.10.008","volume":"4","author":"GA Van Norman","year":"2019","unstructured":"Van Norman GA. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic to Transl Sci. 2019;4:845\u201354.","journal-title":"JACC Basic to Transl Sci."},{"key":"674_CR188","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.pnpbp.2017.04.003","volume":"81","author":"S Yan","year":"2018","unstructured":"Yan S, Tu Z, Li S, Li XJ. Use of CRISPR\/Cas9 to model brain diseases. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;81:488\u201392.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry."},{"key":"674_CR189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"JY Huang","year":"2020","unstructured":"Huang JY, Kan SH, Sandfeld EK, Dalton ND, Rangel AD, Chan Y, et al. CRISPR-Cas9 generated Pompe knock-in murine model exhibits early-onset hypertrophic cardiomyopathy and skeletal muscle weakness. Sci Rep. 2020;10:1\u201313.","journal-title":"Sci Rep"},{"key":"674_CR190","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","volume":"94","author":"T Ohshima","year":"1997","unstructured":"Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, et al. \u03b1-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA. 1997;94:2540\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"674_CR191","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep05396","volume":"4","author":"M Inui","year":"2014","unstructured":"Inui M, Miyado M, Igarashi M, Tamano M, Kubo A, Yamashita S, et al. Rapid generation of mouse models with defined point mutations by the CRISPR\/Cas9 system. Sci Rep. 2014;4:1\u20138.","journal-title":"Sci Rep"},{"key":"674_CR192","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.99171","volume":"3","author":"JJ Miller","year":"2018","unstructured":"Miller JJ, Aoki K, Moehring F, Murphy CA, O\u2019Hara CL, Tiemeyer M, et al. Neuropathic pain in a Fabry disease rat model. JCI Insight. 2018;3:1\u201319.","journal-title":"JCI Insight."},{"key":"674_CR193","doi-asserted-by":"crossref","unstructured":"Adachi T, El-Hattab AW, Jain R, Nogales Crespo KA, Quirland Lazo CI, Scarpa M, et al. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. Int J Environ Res Public Health. 2023;20:4732.","DOI":"10.3390\/ijerph20064732"},{"key":"674_CR194","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.drudis.2019.01.005","volume":"24","author":"DA Fonseca","year":"2019","unstructured":"Fonseca DA, Amaral I, Pinto AC, Cotrim MD. Orphan drugs: major development challenges at the clinical stage. Drug Discov Today. 2019;24:867\u201372.","journal-title":"Drug Discov Today"},{"key":"674_CR195","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/ajmg.a.38413","volume":"176","author":"L Kempf","year":"2018","unstructured":"Kempf L, Goldsmith JC, Temple R. Challenges of developing and conducting clinical trials in rare disorders. Am J Med Genet Part A. 2018;176:773\u201383.","journal-title":"Am J Med Genet Part A"},{"key":"674_CR196","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13023-014-0170-0","volume":"9","author":"SA Bell","year":"2014","unstructured":"Bell SA, Tudur SC. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014;9:170.","journal-title":"Orphanet J Rare Dis"},{"key":"674_CR197","first-page":"139","volume":"176","author":"CH Volmar","year":"2017","unstructured":"Volmar CH, Wahlestedt CBS. Orphan diseases: state of the drug discovery art. Wien Med Wochenschr. 2017;176:139\u201348.","journal-title":"Wien Med Wochenschr"},{"key":"674_CR198","doi-asserted-by":"crossref","unstructured":"Kakkis ED, O\u2019Donovan M, Cox G, Hayes M, Goodsaid F, Tandon PK, et al. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints. Orphanet J Rare Dis. 2015;10:16.","DOI":"10.1186\/s13023-014-0195-4"},{"key":"674_CR199","unstructured":"Committee for Orphan Medicinal Products (COMP) | European Medicines Agency. Ema.europa.ue\/en. https:\/\/www.ema.europa.eu\/en\/committees\/committee-orphan-medicinal-products-comp#:~:text=Role%20of%20the%20COMP&text=The%20COMP%20is%20responsible%20for,life%2Dt."},{"key":"674_CR200","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.drudis.2017.09.015","volume":"23","author":"ME Sheean","year":"2018","unstructured":"Sheean ME, Stoyanova-Beninska V, Capovilla G, Duarte D, Hofer MP, Hoffmann M, et al. Nonclinical data supporting orphan medicinal product designations: lessons from rare neurological conditions. Drug Discov Today. 2018;23:26\u201348.","journal-title":"Drug Discov Today"},{"key":"674_CR201","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.drudis.2017.10.012","volume":"23","author":"MP Hofer","year":"2018","unstructured":"Hofer MP, Hedman H, Mavris M, Koenig F, Vetter T, Posch M, et al. Marketing authorisation of orphan medicines in Europe from 2000 to 2013. Drug Discov Today. 2018;23:424\u201333.","journal-title":"Drug Discov Today"},{"key":"674_CR202","unstructured":"Orphan medicinal product designation. European Medicine Agency. https:\/\/www.ema.europa.eu\/en\/documents\/other\/orphan-medicines-figures-2000-2022_en.pdf. Accessed 16 Apr 2024."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00674-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00674-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T20:25:47Z","timestamp":1724876747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00674-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":202,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00674-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,23]]},"assertion":[{"value":"25 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded by MCIU\/AEI\/FEDER,UE, grant number RTI2018-098672-B-I00, and by the Basque Government, grant number IT1587-22, GIC21\/34. The research grants of M. Beraza-Millor (PIF21\/61) and J. Rodr\u00edguez-Castej\u00f3n (PRE_2020_2_01164) were funded by the University of Basque Country UPV\/EHU and the Basque Government, respectively.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All relevant materials for this systematic review are incorporated in the article, are fully cited, or are supplied as Online Supplementary Material.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MBM: Conceptualization, data curation, methodology, writing \u2013 original draft, writing \u2013 reviewing. ARG: Conceptualization, data curation, methodology, writing \u2013 original draft, writing \u2013 reviewing. MAS: Conceptualization, data curation, methodology, writing \u2013 original draft, writing \u2013 reviewing. JRC: Data curation, methodology, writing \u2013 reviewing. APR: Conceptualization, data curation, methodology, writing \u2013 reviewing. All authors participated in editing and revising the final manuscript and take responsibility for its contents.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}